AFIB (AFIB) Stock Price & Analysis
AFIB (AFIB) rose 0.00% to USD 0 as of June 10, 2026 at 03:09 UTC, according to Nexqual real-time market data.
AFIB last closed at USD 0; the session ranged USD 0–0 on volume of 10,000 shares. Market capitalization is $5,982, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, June 10, 2026 at 03:09 UTC.
Key Statistics (as of June 10, 2026 at 03:09 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 10,000 shares |
| Market Cap | $5,982 |
| Exchange | PNK |
Technical Analysis (AFIB)
Nexqual's technical model rates AFIB "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:09 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 53.39 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (AFIB)
Wall Street analysts rate AFIB "None", per Nexqual as of June 10, 2026 at 03:09 UTC.
| Consensus Rating | None |
|---|
Earnings (AFIB)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -0.52 vs est -0.56 ▲ beat |
| 2023-06-30 | USD -0.6 vs est -0.62 ▲ beat |
| 2023-03-31 | USD -0.59 vs est -0.64 ▲ beat |
| 2022-12-31 | USD -0.63 vs est -0.61 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:09 UTC.
Financials & Fundamentals (AFIB)
| Total Revenue | $20.16M |
|---|---|
| Revenue Growth (YoY) | +203.70% |
| Gross Margin | +5.03% |
| Operating Margin | -21.75% |
| Profit Margin | -47.36% |
| Current Ratio | 2.06 |
| Total Cash | $14.02M |
| Total Debt | $35.76M |
| Free Cash Flow | $-6.78M |
Source: Nexqual, June 10, 2026 at 03:09 UTC.
Financial Health Score (AFIB)
Nexqual rates AFIB's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:09 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $14M cash vs $36M debt |
| Cash Flow | Weak — FCF negative: -$7M, burning cash |
| Efficiency | Mixed — No data |
Ownership (AFIB)
| Insider Ownership | +8.29% |
|---|---|
| Institutional Ownership | +8.85% |
| Shares Outstanding | 29.91M |
| Float | 24.78M |
| Short % of Float | +1.91% |
Source: Nexqual, June 10, 2026 at 03:09 UTC.
Leadership (AFIB)
AFIB is led by Takeo Mukai (age 45), CEO & CFO, per Nexqual as of June 10, 2026 at 03:09 UTC.
| CEO & CFO | Takeo Mukai (age 45) |
|---|
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KRBPQ | Kiromic BioPharma, Inc. | USD 0 | ▲ 0% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 0% |
| REVB | Revelation Biosciences, Inc. | USD 1.04 | ▲ 5.05% |
| BSFC | BLUE STAR FOODS CORP. | USD 0 | ▼ 30% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:09 UTC. This page is informational and not investment advice.